全文获取类型
收费全文 | 44564篇 |
免费 | 2356篇 |
国内免费 | 272篇 |
专业分类
耳鼻咽喉 | 553篇 |
儿科学 | 792篇 |
妇产科学 | 825篇 |
基础医学 | 5722篇 |
口腔科学 | 1403篇 |
临床医学 | 3226篇 |
内科学 | 10883篇 |
皮肤病学 | 1071篇 |
神经病学 | 3122篇 |
特种医学 | 1721篇 |
外科学 | 7887篇 |
综合类 | 260篇 |
一般理论 | 2篇 |
预防医学 | 1366篇 |
眼科学 | 638篇 |
药学 | 2854篇 |
中国医学 | 73篇 |
肿瘤学 | 4794篇 |
出版年
2023年 | 224篇 |
2021年 | 886篇 |
2020年 | 510篇 |
2019年 | 708篇 |
2018年 | 948篇 |
2017年 | 720篇 |
2016年 | 815篇 |
2015年 | 939篇 |
2014年 | 1234篇 |
2013年 | 1378篇 |
2012年 | 2175篇 |
2011年 | 2368篇 |
2010年 | 1292篇 |
2009年 | 1179篇 |
2008年 | 2066篇 |
2007年 | 2192篇 |
2006年 | 2240篇 |
2005年 | 2255篇 |
2004年 | 2172篇 |
2003年 | 2090篇 |
2002年 | 2004篇 |
2001年 | 1330篇 |
2000年 | 1516篇 |
1999年 | 1331篇 |
1998年 | 510篇 |
1997年 | 392篇 |
1996年 | 393篇 |
1995年 | 368篇 |
1994年 | 307篇 |
1993年 | 304篇 |
1992年 | 847篇 |
1991年 | 795篇 |
1990年 | 728篇 |
1989年 | 735篇 |
1988年 | 715篇 |
1987年 | 680篇 |
1986年 | 693篇 |
1985年 | 616篇 |
1984年 | 455篇 |
1983年 | 364篇 |
1979年 | 344篇 |
1978年 | 249篇 |
1977年 | 212篇 |
1975年 | 207篇 |
1974年 | 231篇 |
1973年 | 211篇 |
1972年 | 203篇 |
1971年 | 211篇 |
1970年 | 205篇 |
1969年 | 230篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
Koji Sasaki Tapan Kadia Kebede Begna Courtney D. DiNardo Gautam Borthakur Nicholas J. Short Nitin Jain Naval Daver Elias Jabbour Guillermo Garcia-Manero Guillermo Montalban Bravo Lucia Masarova Sherry Pierce Marina Konopleva Farhad Ravandi Ayalew Tefferi Hagop Kantarjian 《American journal of hematology》2022,97(1):68-78
The progress with intensive chemotherapy and supportive care measures has improved survival in patients with newly diagnosed acute myeloid leukemia (AML). Given the recent development of effective low intensity therapies, an optimal decision on the therapy intensity may improve survival through the avoidance of early mortality. We reviewed the outcome of 3728 patients with newly diagnosed AML who received intensive chemotherapy between August 1980 and May 2020. Intensive chemotherapy was defined as a cumulative cytarabine dose ≥ 700 mg/m2 during induction therapy. We divided the whole cohort into a training and validation group at a 3:1 ratio. The population was divided into a training (2790 patients) and a validation cohort (938 patients). The median age was 55 years (range, 15-99). Among them, 442 patients (12%) had core-binding factor AML. Binary logistic regression identified older age, worse performance status, hyperbilirubinemia, elevated creatinine, hyperuricemia, cytogenetic abnormalities other than CBF and -Y, and pneumonia as adverse prognostic factors for an early 4-week mortality. This risk classification for early mortality was verified in the validation cohort of patients. In the validation cohort of more recently treated patients from 2000 to 2017, the 4-week mortality rates with intensive chemotherapy were 2%, 14%, and 50% in the low-, high-, and very high-risk group, respectively. The mortality rates with low intensity therapies were 3%, 9%, and 20%, respectively. The risk classification guides treatment intensity by the assessment of age, frailty, organ dysfunction, cytogenetic abnormality, and infection to avoid early mortality. 相似文献
2.
3.
Mamiko Onuki Koji Matsumoto Takashi Iwata Kasumi Yamamoto Yoichi Aoki Shoji Maenohara Naotake Tsuda Shoji Kamiura Kazuhiro Takehara Koji Horie Nobutaka Tasaka Hideaki Yahata Yuji Takei Yoichi Aoki Hisamori Kato Takeshi Motohara Keiichiro Nakamura Mitsuya Ishikawa Tatsuya Kato Hiroyuki Yoshida Noriomi Matsumura Hidekatsu Nakai Shogo Shigeta Fumiaki Takahashi Kiichiro Noda Nobuo Yaegashi Hiroyuki Yoshikawa 《Cancer science》2020,111(7):2546-2557
To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012‐2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2‐3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type‐specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type‐specific RCs between CIN1 and CIN2‐3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type‐specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2‐3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2‐3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01‐4.98), followed by HPV31 (2.51, 1.54‐5.24), HPV18 (2.43, 1.59‐4.32), HPV35 (1.56, 0.43‐8.36), HPV33 (1.01, 0.49‐3.31), HPV52 (0.99, 0.76‐1.33), and HPV58 (0.97, 0.75‐1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71‐2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14‐0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9‐valent vaccine contributed to 89.7% (95% CI, 88.7‐90.7) of CIN2‐3/AIS and 93.8% (95% CI, 92.4‐95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9‐valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women. 相似文献
4.
5.
6.
7.
Yui Ito Mitsuaki Ishida Chisato Ohe Chika Miyasaka Koji Tsuta 《Journal of cutaneous pathology》2021,48(1):102-105
Signet‐ring cell/histiocytoid carcinoma (SRCHC) is a very rare skin appendage cancer, with an extremely rare occurrence in the axilla. This study describes the 11th case of SRCHC occurring in the axilla and reports the first gene alteration analysis performed for SRCHC. An 85‐year‐old Japanese male presented with a tumor in the left axilla. Biopsy of the axilla nodule demonstrated diffuse proliferation of histiocytoid neoplastic cells and signet‐ring cells in the dermis and subcutis. Immunohistochemistry revealed loss of E‐cadherin expression in these neoplastic cells. Accordingly, SRCHC of the axilla was diagnosed. Genetic analysis using next‐generation sequencing demonstrated missense mutation of PIK3CA (c1633G>A, pGlu545Lys) and no CDH1 gene mutation.SRCHC of the axilla is considered equivalent to a histiocytoid variant of invasive lobular breast carcinoma. The present SRCHC case demonstrated a pathogenic PIK3CA mutation, which is observed in invasive lobular carcinoma. Additional large case studies are required to clarify the clinicopathological features and gene alterations in SRCHC of the axilla. 相似文献
8.
F.R.L. Sato C.A.A. Lima G. Tralli R.A. da Silva 《International journal of oral and maxillofacial surgery》2019,48(2):233-238
The aim of this study was to evaluate the correlation between clinical signs and symptoms of patients with internal derangement of the temporomandibular joint (TMJ) and arthroscopic findings. The study included a sample of 67 patients who underwent TMJ arthroscopy. The variables evaluated were the arthroscopic findings of synovitis, chondromalacia, adhesion, and roofing. The Spearman correlation index was used to correlate these findings with the clinical signs and symptoms of internal derangement of the TMJ, namely maximum mouth opening, pain (visual analogue scale, VAS), and the Wilkes classification. The mean age of the population was 36.16 years, and 85% were female. There was a correlation between pain and synovitis (P = 0.0029, r = 0.3508), between mouth opening limitation and the amount of adhesion (P = 0.0004, r = ?0.4084), and between Wilkes classification and the presence of chondromalacia and disc displacement (P = 0.001, r = 0.374 and P = 0.0045, r = ?0.3357, respectively). No correlation was found between age and the presence of chondromalacia (P = 0.3444, r = 0.1147). Patients who had worse pain symptoms had more advanced stages of synovitis, and the increased presence of adhesions was associated with limitations in mouth opening. Furthermore, those with more advanced Wilkes stages had greater disc displacement and more severe stages of chondromalacia. 相似文献
9.